PLPP2

Across TCGA pan-cancer cohorts, PLPP2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PLPP2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PLPP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLPP2 expression acts as an unfavorable survival marker.

HNSC, CCRCC, and LUAD are the cancer types where PLPP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.177	1.000	.024	37	view →
CCRCC	DFS	Quartile	All	0.456	1.000	.045	4	view →
LUAD	DFS	Tertile	II,III,IV	0.320	0.891	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PLPP2–HNSC (DFS)

Open the HNSC breakdown →